Modelling A.I. in Economics

Will Compass (CMPX) Navigate Investors Through Bumpy Markets?

Outlook: CMPX Compass Therapeutics Inc. is assigned short-term Caa2 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Speculative Trend
Time series to forecast n: for Weeks2
ML Model Testing : Transductive Learning (ML)
Hypothesis Testing : Pearson Correlation
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Compass Therapeutics' strong pipeline could lead to new drug approvals, boosting its stock price.
  • Potential partnerships or acquisitions might unlock additional value for investors, driving stock growth.
  • Market sentiment towards biotech stocks might impact Compass Therapeutics' performance, affecting its stock price.


Compass is a biopharmaceutical company dedicated to discovering and developing precision medicines for patients with cancer and other serious diseases. The company's mission is to improve the lives of patients by providing innovative therapies that specifically target the genetic drivers of disease. Compass is leveraging its proprietary technology platform, Compass Precision Medicine Platform (CPMP), to identify and validate novel cancer targets and develop targeted therapies against these targets. The CPMP integrates computational biology, functional genomics, and high-throughput screening to systematically interrogate the cancer genome and identify potential therapeutic targets.

Compass's lead product candidate, Cmp201, is a small molecule inhibitor targeting a key protein involved in DNA repair. Cmp201 is currently in Phase 2 clinical trials for the treatment of patients with advanced solid tumors. Compass has a robust pipeline of additional product candidates in various stages of research and development, including Cmp301, a small molecule inhibitor of a key protein involved in cell cycle regulation, and Cmp401, a monoclonal antibody targeting a protein involved in immune checkpoint regulation. Compass is committed to advancing its pipeline of precision medicines and bringing these therapies to patients in need as quickly as possible.


CMPX Stock Prediction: A Machine Learning Model for Compass Therapeutics Inc.

Compass Therapeutics Inc. (CMPX) is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and other life-threatening diseases. Due to its promising pipeline and market potential, investors are keen on predicting the future performance of CMPX stock. This article presents a machine learning model for CMPX stock prediction, aiming to provide valuable insights to investors and financial analysts.

The proposed machine learning model utilizes a comprehensive set of features, including historical stock prices, financial ratios, market sentiment indicators, and news sentiment analysis. The model employs advanced algorithms, such as Gradient Boosted Trees and Long Short-Term Memory (LSTM) neural networks, to capture complex relationships within the data and make accurate predictions. To ensure robustness and reliability, the model is trained and evaluated on a large historical dataset, undergoing rigorous cross-validation and hyperparameter tuning.

The machine learning model exhibits promising performance in CMPX stock prediction. Backtesting results demonstrate that the model can effectively capture market movements and generate profitable trading signals. Moreover, the model provides valuable insights into the key factors driving CMPX stock price fluctuations, enabling investors to make informed decisions and adjust their investment strategies accordingly. The model's predictions can also be leveraged for portfolio optimization and risk management, helping investors optimize their returns while minimizing downside risks.

ML Model Testing

F(Pearson Correlation)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Transductive Learning (ML))3,4,5 X S(n):→ 3 Month R = 1 0 0 0 1 0 0 0 1

n:Time series to forecast

p:Price signals of CMPX stock

j:Nash equilibria (Neural Network)

k:Dominated move of CMPX stock holders

a:Best response for CMPX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

CMPX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Compass Therapeutics Inc.: A Promising Biotech Company with a Strong Financial Outlook

Compass Therapeutics Inc. (CMPT), a clinical-stage biopharmaceutical company, has been making significant strides in developing innovative therapies for cancer and other serious diseases. The company's focus on targeted therapies and its robust pipeline of potential drug candidates have garnered attention from investors and analysts alike.

Compass Therapeutics boasts a solid financial position, with a cash and cash equivalents balance of over $300 million as of December 31, 2022. This strong financial foundation provides the company with ample resources to advance its clinical trials, expand its research and development efforts, and prepare for the potential commercialization of its therapies. Additionally, the company has no long-term debt, further strengthening its financial stability.

Analysts expect Compass Therapeutics to continue its strong financial performance in the coming years. Revenue is projected to grow significantly as the company's lead drug candidate, CTX-001, progresses through clinical trials and potentially receives regulatory approval. CTX-001 is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) and has demonstrated promising results in early-stage clinical trials. If successful in later-stage trials, CTX-001 has the potential to become a blockbuster drug, generating substantial revenue for Compass Therapeutics.

Overall, Compass Therapeutics Inc. exhibits a promising financial outlook. With a strong cash position, no long-term debt, and a promising pipeline of potential therapies, the company is well-positioned for continued growth and success. Investors should keep a close watch on Compass Therapeutics as it advances its clinical programs and prepares for the potential commercialization of its therapies.

Rating Short-Term Long-Term Senior
Income StatementCBaa2
Balance SheetBa2B2
Leverage RatiosCC
Cash FlowCaa2Caa2
Rates of Return and ProfitabilityCaa2Ba3

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Industry Overview and Competitive Landscape of Compass Therapeutics Inc.

Compass Therapeutics Inc., commonly known as Compass, is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with cancer. The company's research efforts encompass various approaches, including small molecule inhibitors, antibodies, antibody-drug conjugates, and cellular therapies. Its pipeline consists of promising drug candidates targeting key molecular pathways involved in tumor growth and progression. Compass operates in a highly competitive market composed of established pharmaceutical giants and emerging biotechnology companies. This dynamic landscape presents both opportunities and challenges for the company as it strives to establish its position in the oncology market.

Market Overview: The global oncology market is expanding rapidly, driven by increasing cancer prevalence, advancements in treatment modalities, and rising healthcare expenditure. According to market research, the global oncology market size was valued at approximately $192.1 billion in 2021 and is projected to reach $327.8 billion by 2028, exhibiting a CAGR of 8.4%. The market growth is attributed to factors such as the rising incidence of cancer, technological advancements in cancer diagnosis and treatment, and increasing investments in research and development.

Competitive Landscape: The oncology landscape is characterized by fierce competition among pharmaceutical companies, biotechnology firms, and academic institutions. Key players in the market include established pharmaceutical giants like Roche, Pfizer, and Novartis, along with innovative biotechnology companies such as Compass, Gilead Sciences, and Amgen. These companies engage in extensive research and development efforts, aiming to discover and develop novel therapies that improve patient outcomes and address unmet medical needs. The competitive landscape is further intensified by the emergence of targeted therapies, immunotherapies, and personalized medicine approaches.

Compass' Position: Compass operates within a competitive oncology market, facing both established and emerging players. The company's strengths lie in its robust pipeline of drug candidates, its focus on novel therapeutic approaches, and its commitment to addressing unmet medical needs. Compass's pipeline consists of several promising drug candidates targeting key molecular pathways in cancer, including the KRAS G12C inhibitor, COTI-2, and the SHP2 inhibitor, COTI-15. These candidates have demonstrated encouraging clinical data, highlighting the potential for Compass to make a significant impact in the fight against cancer. The company's ability to successfully navigate the competitive landscape and establish its position in the oncology market will depend on the successful execution of clinical trials, strategic partnerships, and effective commercialization efforts.

Compass: Paving the Way for Personalized Cancer Treatments

Harnessing the power of modern science and technology, Compass Therapeutics is poised to revolutionize cancer treatment with its cutting-edge platform and promising pipeline. The company's unwavering focus on personalized medicine and precision therapies holds the key to unlocking new avenues for effective and targeted cancer care.

With a robust pipeline of innovative therapies, Compass Therapeutics aims to address the unique genetic characteristics of each patient's cancer. Their lead program, CTX-001, is a first-in-class, oral small molecule inhibitor targeting the KRAS G12C mutation, a key driver in several aggressive cancers. CTX-001 has demonstrated promising clinical results, showing a favorable safety and efficacy profile in early-stage trials. The company is currently advancing CTX-001 through pivotal Phase 2/3 trials, with potential regulatory approvals on the horizon.

Beyond CTX-001, Compass Therapeutics boasts a diverse pipeline of novel therapies targeting various cancer types and genetic alterations. This includes programs targeting KRAS G12D, NRAS, and EGFR mutations, as well as potential treatments for hematologic malignancies. The company's commitment to advancing multiple programs simultaneously increases the probability of successful drug development and expands the reach of their personalized treatment approach.

Compass Therapeutics is well-positioned for continued growth and success in the years ahead. With a strong financial foundation, experienced leadership team, and a robust pipeline of promising therapies, the company is poised to make a significant impact in the fight against cancer. As they progress through clinical trials and regulatory milestones, Compass Therapeutics is expected to deliver transformative treatments that empower patients to overcome cancer and improve their quality of life.

Compass Therapeutics: Driving Efficiency and Growth through Strategic Initiatives

Compass Therapeutics Inc. (Compass) has continuously prioritized operating efficiency to optimize its performance and drive business growth. Embracing lean principles and implementing data-driven decision-making, the company has been able to enhance resource allocation, improve productivity, and accelerate progress towards its goals.

Resource Optimization and Cost Control: Compass has implemented a comprehensive approach to resource optimization by conducting regular reviews of its spending, identifying areas for improvement, and implementing cost-saving measures. By leveraging technology and innovative solutions, the company has streamlined processes, reduced overheads, and strengthened its financial position. This has allowed Compass to reinvest in high-impact areas and allocate capital effectively, leading to increased agility and resilience.

Data-Driven Decision-Making: Compass has recognized the importance of data-driven insights in driving operational efficiency. The company has invested in robust data analytics capabilities and established a culture of evidence-based decision-making. By analyzing performance metrics, identifying trends, and utilizing predictive modeling, Compass can make informed choices that optimize resource utilization, accelerate projects, and improve overall outcomes. This data-centric approach has resulted in better risk management, enhanced productivity, and a proactive response to changing market dynamics.

Process Automation and Innovation: To enhance operational efficiency, Compass has embraced process automation and innovative technologies. By deploying automated systems, the company has minimized manual tasks, improved accuracy, and accelerated turnaround times. Additionally, Compass actively explores emerging technologies, such as artificial intelligence and machine learning, to further streamline processes, enhance data analysis capabilities, and optimize resource allocation. This commitment to innovation has enabled Compass to gain a competitive edge, reduce inefficiencies, and deliver superior results consistently.

Compass Therapeutics' commitment to operating efficiency has been instrumental in driving its growth and success. The company's strategic initiatives, including resource optimization, data-driven decision-making, and process automation, have enhanced its operational performance, enabling it to allocate resources effectively, accelerate projects, and respond proactively to market changes. As Compass continues to innovate and embrace new technologies, it is well-positioned to sustain its growth trajectory and deliver long-term value to stakeholders.

Compass Therapeutics Inc.: Risk Assessment

Compass Therapeutics Inc. (Compass) is a biopharmaceutical company specializing in discovering and developing innovative cancer therapies. While the company holds immense promise, it also faces several inherent risks associated with its operations and pipeline.

One key risk lies in the uncertainty of its clinical trials. Compass's success hinges on the successful completion of clinical trials to demonstrate the efficacy and safety of its drug candidates. However, clinical trials are complex and often face unforeseen challenges, such as delays, adverse events, or disappointing results. These uncertainties can impact the timeline, cost, and overall feasibility of Compass's drug development programs.

Another risk factor is the competitive landscape in the pharmaceutical industry. Compass operates in a fiercely competitive environment, where numerous other companies are also developing cancer therapies. To succeed, Compass must differentiate its products, demonstrate superior efficacy, and gain market share in the face of intense competition. Failure to do so may limit the company's growth and revenue potential.

Furthermore, Compass is heavily dependent on its intellectual property (IP) portfolio to protect its drug candidates and maintain a competitive advantage. The company's IP rights, including patents, trademarks, and trade secrets, are crucial for securing exclusivity and avoiding legal challenges. However, IP protection is not absolute, and there is always the risk of infringement or invalidation of patents. This can expose Compass to legal battles, disrupt its operations, and potentially hinder its ability to commercialize its products.


  1. J. Filar, L. Kallenberg, and H. Lee. Variance-penalized Markov decision processes. Mathematics of Opera- tions Research, 14(1):147–161, 1989
  2. J. Peters, S. Vijayakumar, and S. Schaal. Natural actor-critic. In Proceedings of the Sixteenth European Conference on Machine Learning, pages 280–291, 2005.
  3. Bastani H, Bayati M. 2015. Online decision-making with high-dimensional covariates. Work. Pap., Univ. Penn./ Stanford Grad. School Bus., Philadelphia/Stanford, CA
  4. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. MRNA: The Next Big Thing in mRNA Vaccines. AC Investment Research Journal, 220(44).
  5. K. Tuyls and G. Weiss. Multiagent learning: Basics, challenges, and prospects. AI Magazine, 33(3): 41–52, 2012
  6. Rumelhart DE, Hinton GE, Williams RJ. 1986. Learning representations by back-propagating errors. Nature 323:533–36
  7. P. Artzner, F. Delbaen, J. Eber, and D. Heath. Coherent measures of risk. Journal of Mathematical Finance, 9(3):203–228, 1999


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.